Jun 21 2021


9:00 am - 1:30 pm

Theralymph Work Progress Meeting

Due to the restrictive and preventive measures put into place by the European countries, we met on June 21st 2021 by videoconference.

We were honored to introduce our consortium: Dr Kari Alitalo (Finland), Dr Tatiana Petrova (Switzerland), Dr Miikka Vikkula (Belgium), Dr Agnès Noël (Belgium), Dr Lenka Romeislova (Czeck Republic), Dr Gilles Pagès (France), Dr Taija Makinen (Sweden), Flash Therapeutics (France), the Clinical Investigation Center of Toulouse (France) and Inserm Tranfert.

Introduction : Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 120 million people worldwide, however there is no curative treatment for lymphedema. Therefore, our main objective will be to establish a multiple gene therapy for lymphedema. We will focus on women who developed secondary lymphedema after breast cancer. This meeting will consist in presenting the work teams as well as the distribution of each work packages in Theralymph project.

Hourly Schedule

Theralymph Work Progress Meeting

09:00 - 09:30
WP1 Pathophysiology of lymphedema: risk factor associated with lymphedema - PARTNER PRESENTATIONS
Gilles Pages (CNRS) The ambivalent roles of VEGFC in the aggressiveness and the response to chemotherapy by taxane on breast cancers Anne-Catherine Prats (Inserm) Chemotherapy-induced translational regulation of VEGFC translation through specialized ribosomes
09:00 - 09:30
09:40 - 10:25
WP2 - Architecture of the collecting vessels in the adipose tissue - PARTNER PRESENTATIONS
Taija Mâkinen laboratory (UU) - Update on single cell transcriptome analysis of LECs Kari Alitalo (UnivHel) WP2 progress update Miika Vikkula (DDUV) RNAseq analysis of lymphatic malformations and secondary lymphedemas
10:25 - 10:35
10:35 - 10:50
WP3 - Adipocyte dysfunction in lymphedema - PARTNER PRESENTATIONS
Lenka Rossmeislova (CUNI) Adipocyte-HDLEC interactions- impact on lipid handling genes and lymphatic vessels
10:50 - 10:55
10:55 - 11:10
Pause cafe
11:10 - 11:25
WP4 - Resolution of inflammation in lymphedema - PARTNER PRESENTATIONS
Tatiana Petrova (UNIL) Cross-talk of inflammation and mechanotransduction in lymphedema
11:25 - 11:30
11:30 - 11:45
WP5 - Validation of therapeutic targets in vitro - PARTNER PRESENTATIONS
Agnes Noël (ULIEGE) In vitro lymphatic endothelial cell features.
11:45 - 11:50
11:50 - 12:50
WP6 Validation of therapeutic targets in vivo in mice model of lymhedema - PARTNER PRESENTATIONS
Justine Creff (Inserm) Effect of monocistronic versus bicistronic vectors in lymphedema: VEGFC coupled to Apelin, VEGFD, FGF1 and FGF2 Regis Gayon (FTX) Backward planning for the cGMP LentiFlash production Sawan Kumar Jha (UnivHel) VEGFC coupled with Angiopioetin2 Alizée Lebeau (ULIEGE) Characterization of lymphedema model induced by irradiation and surgery
12:50 - 13:00
13:00 - 13:10
First Periodic Report to the commission
Christiane Dascher-Nadel (IT) Presentation of the Report PR1 incl. Timelines
13:10 - 13:30